FlyBase Allele Report: Dmel\Lrrk[I1915T.UAS]

General Information

Symbol

Dmel\Lrrk^I1915T.UAS

Species

D. melanogaster

Name

FlyBase ID

FBal0220788

Feature type

allele

Associated gene

Dmel\Lrrk

Associated Insertion(s)

Carried in Construct

P{UAS-Lrrk.I1915T}

Also Known As

UAS-Lrrk^I1915T, UAS-dLRRK I1915T, UAS-dLRRK-I1915T, UAS-Lrrk I1915T

Key Links

Genomic Maps

JBrowse

Transgenic product class

missense_variant

(Imai et al., 2008)

Mutagen

in vitro construct

Nature of the Allele

Transgenic product class

missense_variant

(Imai et al., 2008)

Mutagen

in vitro construct

(Imai et al., 2008)

Progenitor genotype

Carried in construct

P{UAS-Lrrk.I1915T}

Cytology

Description

Amino acid replacement: I1915T.

(Imai et al., 2008)

UAS regulatory sequences drive expression of a mutated form of Lrrk.

(Imai et al., 2008)

Allele components

Component

Use(s)

Regulatory region(s)

UAS

binary expression system - regulatory region

Encoded product / tool

Lrrk

Mutations Mapped to the Genome

Curation Data

Type

Location

Additional Notes

References

point_mutation

3R:20,642,367..20,642,367 [+]

Comment:

The I1915T mutation was reported relative to Lrrk-RB. analogous mutation in human LRRK2 implicated in Parkinson;disease 8; mutation carried on in vitro construct; site of nucleotide substitution in fly gene and specific disease association inferred by FlyBase curator.

(Imai et al., 2008)

Variant Molecular Consequences

Associated Sequence Data

DDBJ / EMBL / GenBank

DNA sequence

Protein sequence

UniProtKB/Swiss-Prot

UniProtKB/TrEMBL

Expression Data

Reporter Expression

Additional Information

Statement

Reference

Marker for

Reflects expression of

Reporter construct used in assay

Human Disease Associations

Disease Ontology (DO) Annotations

Models Based on Experimental Evidence ( 1 )

Disease

Evidence

References

model of Parkinson's disease 8

CEC

(Inoshita et al., 2022)

CEA

(Stickley et al., 2023, Miozzo et al., 2022, Sarkar et al., 2021)

model of Parkinson's disease

CEA

(Imai et al., 2008)

CEC

(Gehrke et al., 2010)

Modifiers Based on Experimental Evidence ( 1 )

Disease

Interaction

References

model of Parkinson's disease 8

is exacerbated by Fer2^MB09480

(Miozzo et al., 2022)

is ameliorated by Fer2^{fTRG00336.sfGFP-TVPTBF}

(Miozzo et al., 2022)

model of Parkinson's disease

is ameliorated by Thor^TA.UAS

(Imai et al., 2008)

is ameliorated by E2f1⁰⁷¹⁷²

(Gehrke et al., 2010)

is ameliorated by mir-184^UAS.cGa

(Gehrke et al., 2010)

is ameliorated by Dcr-1^UAS.cDa

(Gehrke et al., 2010)

is exacerbated by Dcr-1^VDRC.cUa

(Gehrke et al., 2010)

is ameliorated by mir-let7^UAS.cGa

(Gehrke et al., 2010)

is exacerbated by AGO1^k08121

(Gehrke et al., 2010)

is ameliorated by Rbf^UAS.cDa

(Gehrke et al., 2010)

is ameliorated by Dp^49Fk-1

(Gehrke et al., 2010)

is exacerbated by Dcr-1^RNAi.UAS.cUa

(Gehrke et al., 2010)

exacerbates tauopathy

modeled by Hsap\MAPT^R406W.UAS

(Bardai et al., 2018)

exacerbates Parkinson's disease 1

modeled by Hsap\SNCA^QUAS.cOa

(Sarkar et al., 2021)

Comments on Models/Modifiers Based on Experimental Evidence ( 0 )

Disease-implicated variant(s)

This allele represents a human variant implicated in disease.

(Imai et al., 2008)

LRRK2:p.Ile2020Thr

(FlyBase curators, 2019-)

Variants Synonym(s)

Associated human disease model(s)

Parkinson disease 8

External database links

ClinVar: LRRK2_1941

Comments concerning this variant

Phenotypic Data

Phenotypic Class

Phenotype Manifest In

Detailed Description

Statement

Reference

Adults expressing Lrrk^I1915T.UAS under the control of Scer\GAL4^Fer2.2359 or Scer\GAL4^GMR58E02 show a progressive decrease in the number of PAM neurons.

(Miozzo et al., 2022)

Flies expressing Lrrk^{I1915T.Scer\UAS} under the control of Scer\GAL4^ple.PG do not show a progressive reduction in electroretinogram amplitude (there is no significant difference in the amplitude seen in 3 and 28 day old flies).

(Hindle et al., 2013)

Expression of Lrrk^{I1915T.Scer\UAS} driven by Scer\GAL4^ple.PF leads to dopaminergic neuron loss.

(Gehrke et al., 2010)

Expression of Lrrk^{I1915T.Scer\UAS} under the control of Scer\GAL4^GMR.PF does not result in any apparent eye degeneration.

(Kanao et al., 2010)

Pre-synaptic or post-synaptic expression of Lrrk^{I1915T.Scer\UAS} (under the control of either Scer\GAL4^elav-C155 or Scer\GAL4^Mhc.PW) results in an estimated 20% decrease in the total number of type I boutons and neuromuscular junction branch number on muscle 6/7 of A3, with no observable effect on muscle size. Neuromuscular length is normal.

(Lee et al., 2010)

60 day old adults expressing Lrrk^{I1915T.Scer\UAS} under the control of Scer\GAL4^ple.PF show a significant reduction in the number of dopaminergic neurons in the protocerebral posterior medial 1 and 2 clusters and in the protocerebral posterior lateral 1 cluster compared to control flies, although the number of neurons in the protocerebral posterior medial 3 cluster is unaffected in the mutant flies.

Flies expressing Lrrk^{I1915T.Scer\UAS} under the control of Scer\GAL4^da.G32 show significantly higher sensitivity to paraquat and to hydrogen peroxide compared to control flies.

Expression of Lrrk^{I1915T.Scer\UAS} under the control of Scer\GAL4^elav-C155 results in locomotor dysfunction with age (45 day old flies show significantly reduced climbing ability compared to controls).

(Imai et al., 2008)

External Data

Linkouts

Interactions

Show genetic interaction network for Enhancers & Suppressors

Phenotypic Class

Enhanced by

Statement

Reference

Lrrk^I1915T.UAS, Scer\GAL4^Fer2.2359 has decreased cell number | adult stage | progressive phenotype, enhanceable by Fer2^MB09480/Fer2^MB09480

(Miozzo et al., 2022)

Lrrk^I1915T.UAS, Scer\GAL4^Fer2.2359 has abnormal neuroanatomy | adult stage | progressive phenotype, enhanceable by Fer2^MB09480/Fer2^MB09480

(Miozzo et al., 2022)

Lrrk^I1915T.UAS, Scer\GAL4^ple.PF has abnormal neuroanatomy phenotype, enhanceable by Dcr-1^RNAi.UAS.cUa, Scer\GAL4^ple.PF

(Gehrke et al., 2010)

Lrrk^I1915T.UAS, Scer\GAL4^GMR.PF, foxo^UAS.cKb has visible phenotype, enhanceable by Diap1^th-1/th[+]

(Kanao et al., 2010)

NOT Enhanced by

Statement

Reference

Lrrk^I1915T.UAS, Scer\GAL4^ple.PF has abnormal neuroanatomy phenotype, non-enhanceable by lkb1[+]/Lkb1^4A4-2

(Gehrke et al., 2010)

Suppressed by

Statement

Reference

Lrrk^I1915T.UAS, Scer\GAL4^GMR58E02 has abnormal neuroanatomy | adult stage | progressive phenotype, suppressible | partially by Fer2^{fTRG00336.sfGFP-TVPTBF}

(Miozzo et al., 2022)

Lrrk^I1915T.UAS, Scer\GAL4^GMR58E02 has decreased cell number | adult stage | progressive phenotype, suppressible | partially by Fer2^{fTRG00336.sfGFP-TVPTBF}

(Miozzo et al., 2022)

Lrrk^I1915T.UAS, Scer\GAL4^ple.PF has abnormal neuroanatomy phenotype, suppressible by Dcr-1^UAS.cDa, Scer\GAL4^ple.PF

(Gehrke et al., 2010)

Lrrk^I1915T.UAS, Scer\GAL4^ple.PF has abnormal neuroanatomy phenotype, suppressible by E2f[+]/E2f1⁰⁷¹⁷²

(Gehrke et al., 2010)

Lrrk^I1915T.UAS, Scer\GAL4^ple.PF has abnormal neuroanatomy phenotype, suppressible by Dp[+]/Dp^49Fk-1

(Gehrke et al., 2010)

Lrrk^I1915T.UAS, Scer\GAL4^ple.PF has abnormal neuroanatomy phenotype, suppressible by Rbf^UAS.cDa, Scer\GAL4^ple.PF

(Gehrke et al., 2010)

Lrrk^I1915T.UAS, Scer\GAL4^ple.PF has abnormal neuroanatomy phenotype, suppressible | partially by mir-let7^UAS.cGa, Scer\GAL4^ple.PF

(Gehrke et al., 2010)

Lrrk^I1915T.UAS, Scer\GAL4^ple.PF has abnormal neuroanatomy phenotype, suppressible | partially by mir-184^UAS.cGa, Scer\GAL4^ple.PF

(Gehrke et al., 2010)

Lrrk^I1915T.UAS, Scer\GAL4^{elav.Switch.PO}, foxo^UAS.cKb has abnormal neuroanatomy | adult stage | RU486 conditional phenotype, suppressible by W[+]/hid¹

(Kanao et al., 2010)

Lrrk^I1915T.UAS, Scer\GAL4^GMR.PF, foxo^UAS.cKb has visible phenotype, suppressible | partially by Dronc^KG02994/Nc[+]

(Kanao et al., 2010)

Lrrk^I1915T.UAS, Scer\GAL4^GMR.PF, foxo^UAS.cKb has visible phenotype, suppressible | partially by W[+]/hid¹

(Kanao et al., 2010)

Lrrk^I1915T.UAS, Scer\GAL4^da.G32 has chemical sensitive phenotype, suppressible by eIF4E1⁰⁷²³⁸/eIF-4E[+]

(Imai et al., 2008)

Lrrk^I1915T.UAS, Scer\GAL4^ple.PF has abnormal neuroanatomy | adult stage phenotype, suppressible by Thor^UAS.cMa, Scer\GAL4^ple.PF

(Imai et al., 2008)

Lrrk^I1915T.UAS, Scer\GAL4^elav-C155 has abnormal locomotor behavior | adult stage phenotype, suppressible by Thor^TA.UAS, Scer\GAL4^elav-C155

(Imai et al., 2008)

NOT suppressed by

Statement

Reference

Lrrk^I1915T.UAS, Scer\GAL4^ple.PF has abnormal neuroanatomy phenotype, non-suppressible by lkb1[+]/Lkb1^4A4-2

(Gehrke et al., 2010)

Enhancer of

Statement

Reference

Scer\GAL4^Fer2.2359/Lrrk^I1915T.UAS is an enhancer of abnormal neuroanatomy | adult stage | progressive phenotype of Fer2^MB09480

(Miozzo et al., 2022)

Scer\GAL4^Fer2.2359/Lrrk^I1915T.UAS is an enhancer of decreased cell number | adult stage | progressive phenotype of Fer2^MB09480

(Miozzo et al., 2022)

Scer\GAL4^nSyb.PP/Lrrk^I1915T.UAS is an enhancer of decreased cell number | adult stage phenotype of Hsap\SNCA^QUAS.cOa, Ncra\QF^QF2.nSyb

(Sarkar et al., 2021)

Scer\GAL4^nSyb.PP/Lrrk^I1915T.UAS is an enhancer of abnormal locomotor behavior | adult stage phenotype of Hsap\SNCA^QUAS.cOa, Ncra\QF^QF2.nSyb

(Sarkar et al., 2021)

Lrrk^I1915T.UAS, Scer\GAL4^GMR.PF is an enhancer of visible phenotype of Scer\GAL4^GMR.PF, for^P1.UAS, foxo^UAS.cPa

(Kanao et al., 2012)

Lrrk^I1915T.UAS, Scer\GAL4^{elav.Switch.PO} is an enhancer | RU486 conditional of abnormal neuroanatomy | adult stage | RU486 conditional phenotype of Scer\GAL4^{elav.Switch.PO}, for^P1.UAS, foxo^UAS.cPa

(Kanao et al., 2012)

Lrrk^I1915T.UAS, Scer\GAL4^{elav.Switch.PO} is an enhancer | RU486 conditional of abnormal locomotor behavior | adult stage | RU486 conditional phenotype of Scer\GAL4^{elav.Switch.PO}, for^P1.UAS, foxo^UAS.cPa

(Kanao et al., 2012)

Lrrk^I1915T.UAS, Scer\GAL4^GMR.PF is an enhancer of visible phenotype of Scer\GAL4^GMR.PF, foxo^UAS.cKb

(Kanao et al., 2010)

Suppressor of

Statement

Reference

Lrrk^I1915T.UAS, Scer\GAL4^GMR.PFa is a suppressor | partially of visible | adult stage phenotype of Scer\GAL4^GMR.PFa, egr^UAS.cMa

(Ruan et al., 2016)

Other

Statement

Reference

Lrrk^I1915T.UAS, Scer\GAL4^{elav.Switch.PO}, foxo^UAS.cKb has short lived | RU486 conditional phenotype

(Kanao et al., 2010)

Lrrk^I1915T.UAS, Scer\GAL4^{elav.Switch.PO}, foxo^UAS.cKb has abnormal neuroanatomy | adult stage | RU486 conditional phenotype

(Kanao et al., 2010)

Lrrk^I1915T.UAS, Scer\GAL4^{elav.Switch.PO}, foxo^UAS.cKb has abnormal locomotor behavior | adult stage | RU486 conditional phenotype

(Kanao et al., 2010)

Phenotype Manifest In

Enhanced by

Statement

Reference

Lrrk^I1915T.UAS, Scer\GAL4^Fer2.2359 has adult dopaminergic PAM neuron | adult stage | decreased number phenotype, enhanceable by Fer2^MB09480/Fer2^MB09480

(Miozzo et al., 2022)

Lrrk^I1915T.UAS, Scer\GAL4^ple.PF has dopaminergic neuron phenotype, enhanceable by Dcr-1^RNAi.UAS.cUa, Scer\GAL4^ple.PF

(Gehrke et al., 2010)

Lrrk^I1915T.UAS, Scer\GAL4^GMR.PF, foxo^UAS.cKb has eye phenotype, enhanceable by Diap1^th-1/th[+]

(Kanao et al., 2010)

NOT Enhanced by

Statement

Reference

Lrrk^I1915T.UAS, Scer\GAL4^ple.PF has dopaminergic neuron phenotype, non-enhanceable by lkb1[+]/Lkb1^4A4-2

(Gehrke et al., 2010)

Suppressed by

Statement

Reference

Lrrk^I1915T.UAS, Scer\GAL4^GMR58E02 has adult dopaminergic PAM neuron | adult stage | decreased number phenotype, suppressible | partially by Fer2^{fTRG00336.sfGFP-TVPTBF}

(Miozzo et al., 2022)

Lrrk^I1915T.UAS, Scer\GAL4^ple.PF has dopaminergic neuron phenotype, suppressible | partially by mir-let7^UAS.cGa, Scer\GAL4^ple.PF

(Gehrke et al., 2010)

Lrrk^I1915T.UAS, Scer\GAL4^ple.PF has dopaminergic neuron phenotype, suppressible | partially by mir-184^UAS.cGa, Scer\GAL4^ple.PF

(Gehrke et al., 2010)

Lrrk^I1915T.UAS, Scer\GAL4^ple.PF has dopaminergic neuron phenotype, suppressible by Dcr-1^UAS.cDa, Scer\GAL4^ple.PF

(Gehrke et al., 2010)

Lrrk^I1915T.UAS, Scer\GAL4^ple.PF has dopaminergic neuron phenotype, suppressible by E2f[+]/E2f1⁰⁷¹⁷²

(Gehrke et al., 2010)

Lrrk^I1915T.UAS, Scer\GAL4^ple.PF has dopaminergic neuron phenotype, suppressible by Dp[+]/Dp^49Fk-1

(Gehrke et al., 2010)

Lrrk^I1915T.UAS, Scer\GAL4^ple.PF has dopaminergic neuron phenotype, suppressible by Rbf^UAS.cDa, Scer\GAL4^ple.PF

(Gehrke et al., 2010)

Lrrk^I1915T.UAS, Scer\GAL4^{elav.Switch.PO}, foxo^UAS.cKb has dopaminergic neuron | RU486 conditional phenotype, suppressible by W[+]/hid¹

(Kanao et al., 2010)

Lrrk^I1915T.UAS, Scer\GAL4^{elav.Switch.PO}, foxo^UAS.cKb has dopaminergic PPL1 neuron | RU486 conditional phenotype, suppressible by W[+]/hid¹

(Kanao et al., 2010)

Lrrk^I1915T.UAS, Scer\GAL4^GMR.PF, foxo^UAS.cKb has eye phenotype, suppressible | partially by Dronc^KG02994/Nc[+]

(Kanao et al., 2010)

Lrrk^I1915T.UAS, Scer\GAL4^GMR.PF, foxo^UAS.cKb has eye phenotype, suppressible | partially by W[+]/hid¹

(Kanao et al., 2010)

Lrrk^I1915T.UAS, Scer\GAL4^ple.PF has dopaminergic neuron phenotype, suppressible by Thor^UAS.cMa, Scer\GAL4^ple.PF

(Imai et al., 2008)

NOT suppressed by

Statement

Reference

Lrrk^I1915T.UAS, Scer\GAL4^ple.PF has dopaminergic neuron phenotype, non-suppressible by lkb1[+]/Lkb1^4A4-2

(Gehrke et al., 2010)

Enhancer of

Statement

Reference

Scer\GAL4^Fer2.2359/Lrrk^I1915T.UAS is an enhancer of adult dopaminergic PAM neuron | adult stage | decreased number phenotype of Fer2^MB09480

(Miozzo et al., 2022)

Scer\GAL4^nSyb.PP/Lrrk^I1915T.UAS is an enhancer of outer medulla | adult stage phenotype of Hsap\SNCA^QUAS.cOa, Ncra\QF^QF2.nSyb

(Sarkar et al., 2021)

Scer\GAL4^nSyb.PP/Lrrk^I1915T.UAS is an enhancer of medulla intrinsic columnar neuron | adult stage | decreased number phenotype of Hsap\SNCA^QUAS.cOa, Ncra\QF^QF2.nSyb

(Sarkar et al., 2021)

Scer\GAL4^nSyb.PP/Lrrk^I1915T.UAS is an enhancer of dopaminergic medulla neuron | adult stage | decreased number phenotype of Hsap\SNCA^QUAS.cOa, Ncra\QF^QF2.nSyb

(Sarkar et al., 2021)

Lrrk^I1915T.UAS, Scer\GAL4^GMR.PF is an enhancer of eye phenotype of Scer\GAL4^GMR.PF, for^P1.UAS, foxo^UAS.cPa

(Kanao et al., 2012)

Lrrk^I1915T.UAS, Scer\GAL4^{elav.Switch.PO} is an enhancer | RU486 conditional of eye | RU486 conditional phenotype of Scer\GAL4^{elav.Switch.PO}, for^P1.UAS, foxo^UAS.cPa

(Kanao et al., 2012)

Lrrk^I1915T.UAS, Scer\GAL4^GMR.PF is an enhancer of eye phenotype of Scer\GAL4^GMR.PF, foxo^UAS.cKb

(Kanao et al., 2010)

Suppressor of

Statement

Reference

Lrrk^I1915T.UAS, Scer\GAL4^GMR.PFa is a suppressor | partially of eye phenotype of Scer\GAL4^GMR.PFa, egr^UAS.cMa

(Ruan et al., 2016)

Other

Statement

Reference

Lrrk^I1915T.UAS, Scer\GAL4^{elav.Switch.PO}, foxo^UAS.cKb has dopaminergic neuron | RU486 conditional phenotype

(Kanao et al., 2010)

Lrrk^I1915T.UAS, Scer\GAL4^{elav.Switch.PO}, foxo^UAS.cKb has dopaminergic PPL1 neuron | RU486 conditional phenotype

(Kanao et al., 2010)

Lrrk^I1915T.UAS, Scer\GAL4^{elav.Switch.PO}, foxo^UAS.cKb has dopaminergic PPM3 neuron | RU486 conditional phenotype

(Kanao et al., 2010)

Additional Comments

Genetic Interactions

Statement

Reference

The dot-like small eye phenotype characteristic for flies expressing egr^Scer\UAS.cMa under the control of Scer\GAL4^GMR.PFa is strongly suppressed by co-expression of Lrrk^{I1915T.Scer\UAS}.

(Ruan et al., 2016)

Co-expression of foxo^Scer\UAS.cPa and for^P1.Scer\UAS under the control of Scer\GAL4^GMR.PF results in degeneration of the eye. The severity of this phenotype is enhanced by co-expression of Lrrk^{I1915T.Scer\UAS}.

Co-expression of for^P1.Scer\UAS and Lrrk^{I1915T.Scer\UAS} under the control of Scer\GAL4^GMR.PF results in flies with normal eyes.

Co-expression of foxo^Scer\UAS.cPa and for^P1.Scer\UAS under the control of Scer\GAL4^{elav.Switch.PO} in the presence of RU486 results in loss of dopaminergic neurons. This phenotype is enhanced by co-expression of Lrrk^{I1915T.Scer\UAS}.

Co-expression of foxo^Scer\UAS.cPa and for^P1.Scer\UAS under the control of Scer\GAL4^{elav.Switch.PO} in the presence of RU486 results in flies with reduced climbing ability. This phenotype is worsened by co-expression of Lrrk^{I1915T.Scer\UAS}.

(Kanao et al., 2012)

In flies expressing Lrrk^{I1915T.Scer\UAS} driven by Scer\GAL4^ple.PF, Dcr-1^Scer\UAS.cDa-overexpression suppresses the neuronal toxicity of Lrrk^{I1915T.Scer\UAS}.

In flies expressing Lrrk^{I1915T.Scer\UAS} driven by Scer\GAL4^ple.PF, Dcr-1^VDRC.cUa-overexpression exacerbates the neuronal toxicity of Lrrk^{I1915T.Scer\UAS}.

Heterozygosity for E2f⁰⁷¹⁷² suppresses the dopaminergic neuronal phenotypes in animals expressing Lrrk^{I1915T.Scer\UAS} under the control of Scer\GAL4^ple.PF.

Heterozygosity for Dp^49Fk-1 suppresses the dopaminergic neuronal phenotypes in animals expressing Lrrk^{I1915T.Scer\UAS} under the control of Scer\GAL4^ple.PF.

Overexpression of Rbf^Scer\UAS.cDa suppresses the dopaminergic neuronal phenotypes in animals expressing Lrrk^{I1915T.Scer\UAS} under the control of Scer\GAL4^ple.PF.

Heterozygosity for lkb1^4A4-2 has no effect on the dopaminergic neuronal phenotypes in animals expressing Lrrk^{I1915T.Scer\UAS} under the control of Scer\GAL4^ple.PF.

Overexpression of let-7^Scer\UAS.cGa partly suppresses the dopaminergic neuronal phenotypes of Lrrk^{I1915T.Scer\UAS}-expression via Scer\GAL4^ple.PF.

Overexpression of mir-184^Scer\UAS.cGa partly suppresses the dopaminergic neuronal phenotypes of Lrrk^{I1915T.Scer\UAS}-expression via Scer\GAL4^ple.PF.

(Gehrke et al., 2010)

The severity of the eye defects caused by expression of foxo^Scer\UAS.cKb under the control of Scer\GAL4^GMR.PF are enhanced by co-expression of Lrrk^{I1915T.Scer\UAS}.

Co-expression of foxo^Scer\UAS.cKb and Lrrk^{I1915T.Scer\UAS} under the control of Scer\GAL4^{elav.Switch.PO} in the presence of RU486 throughout the lifespan results in a reduction in lifespan. These flies show an age-dependent decrease in the number of PPM1/2, PPM3 and PPL1 neurons and 1 day old flies show a defect in climbing ability.

Co-expression of foxo^{S259A.Scer\UAS} and Lrrk^{I1915T.Scer\UAS} under the control of Scer\GAL4^{elav.Switch.PO} in the presence of RU486 throughout the lifespan does not have an effect on lifespan. The flies do not show loss of dopaminergic neurons PAL, PPM1/2, PPM3 or PPL1.

The eye phenotype caused by co-expression of foxo^Scer\UAS.cKb and Lrrk^{I1915T.Scer\UAS} under the control of Scer\GAL4^GMR.PF is significantly suppressed if the flies also carry either Nc^KG02994/+ or W¹/+.

The eye phenotype caused by co-expression of foxo^Scer\UAS.cKb and Lrrk^{I1915T.Scer\UAS} under the control of Scer\GAL4^GMR.PF is enhanced by th¹/+.

The degeneration of the PPM1/2 and PPL1 neurons which is seen in flies co-expressing foxo^Scer\UAS.cKb and Lrrk^{I1915T.Scer\UAS} under the control of Scer\GAL4^{elav.Switch.PO} in the presence of RU486 is suppressed if they alo carry W¹/+.

(Kanao et al., 2010)

The increased sensitivity to paraquat that is seen in flies expressing Lrrk^{I1915T.Scer\UAS} under the control of Scer\GAL4^da.G32 is suppressed to wild-type levels of sensitivity if the flies are also heterozygous for eIF-4E⁰⁷²³⁸.

The decrease in the number of dopaminergic neurons in the protocerebral posterior medial 1 and 2 clusters and in the protocerebral posterior lateral 1 cluster that is seen in 60 day old adults expressing Lrrk^{I1915T.Scer\UAS} under the control of Scer\GAL4^ple.PF is suppressed by co-expression of Thor^Scer\UAS.cMa.

The reduced climbing ability that is seen in 45 day old flies expressing Lrrk^{I1915T.Scer\UAS} under the control of Scer\GAL4^elav-C155 is partially rescued by co-expression of Thor^TA.Scer\UAS.

(Imai et al., 2008)

Xenogenetic Interactions

Statement

Reference

Complementation and Rescue Data

Comments

Images (0)

Mutant

Wild-type

Stocks (0)

Notes on Origin

Discoverer

External Crossreferences and Linkouts ( 0 )

Synonyms and Secondary IDs (4)

Reported As

Symbol Synonym

Lrrk^{I1915T.Scer\UAS}

Lrrk^I1915T.UAS

dLRRK I1915T

(Iyer et al., 2016)

dLRRK^I1915T

(Ruan et al., 2016)

Name Synonyms

Secondary FlyBase IDs

References (15)

Report Sections

Open Close